Please assess the completion status of the following clinical trial:

Trial Title: Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically proven adenocarcinoma of the prostate prior to the initiation of radiotherapy~* Prior pelvic radiotherapy for prostate cancer, either post-radical prostatectomy or as primary management~  * More than 30 months since prior brachytherapy with curative intent~* Prostate-specific antigen must be rising and greater than 3 ng/mL and higher than the lowest level recorded previously since the end of radiotherapy (i.e., higher than the post-radiotherapy nadir)~* Total testosterone greater than 5 nmol/L~* No definite evidence of metastatic disease~  * Chest x-ray and bone scan negative for metastases~ * Radiological changes compatible with nonmalignant diseases allowed~* Clinical evidence of local disease allowed~PATIENT CHARACTERISTICS:~Age:~* 16 and over (18 and over for participating centers in the United Kingdom)~Performance status:~* ECOG 0-1~Life expectancy:~* More than 5 years~Hematopoietic:~* Not specified~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* AST/ALT no greater than 1.5 times ULN~* LDH no greater than 1.5 times ULN~* No chronic liver disease~Renal:~* Creatinine no greater than 1.5 times ULN~Other:~* Sufficiently fluent and willing to complete the quality of life questionnaire in either English or French~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except curatively treated basal or squamous cell skin cancer or superficial bladder cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior or concurrent biologic therapy~Chemotherapy:~* No prior or concurrent chemotherapy~Endocrine therapy:~* Prior hormonal therapy administered prior to, during, or immediately after radical radiotherapy or prostatectomy allowed provided duration was no longer than 12 months~  * At least 12 months since prior hormonal therapy~Radiotherapy:~* See Disease Characteristics~* At least 12 months since prior radiotherapy~* No concurrent palliative radiotherapy~Surgery:~* See Disease Characteristics~* See Endocrine therapy~Other:~* No concurrent bisphosphonates

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Intermittent Androgen Suppression (Type: ACTIVE_COMPARATOR): None
- Continuous Androgen Suppression (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).